Expert to Present Data on CDI Patients at Risk of Recurrence and Mortality at SHEA Annual Meeting
Optimer Pharmaceuticals, Inc. announces that data highlighting the burden of Clostridium difficile infection using national health insurance claims and survey databases will be presented on April 2, 2011 at the 21st annual scientific meeting of the Society for Healthcare Epidemiology of America (SHEA).
Erik R. Dubberke, MD, MSPH, of Washington University School of Medicine in St. Louis, will present the poster, "Rates of Recurrence and Mortality Among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey Databases on Saturday, April 2, 2011 from 1 p.m. to 2:15 p.m. CT in the Trinity Ballroom at the Hilton Anatole Hotel in Dallas.
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development.
Endoscopes and Lumened Instruments: New Studies Highlight Persistent Contamination Risks
May 7th 2025Two new studies reveal troubling contamination in both new endoscopes and cleaned lumened surgical instruments, challenging the reliability of current reprocessing practices and manufacturer guidelines.
